Navana Pharmaceuticals PLC
DDSE:NAVANAPHAR61.60
BDT
+1.00
(+1.65%)
ISIN
BD0497NAVPH5
Return %
Stock
S&P 500
1Y
24.19
14.20
3Y
-28.87
81.12
5Y
- -
68.34
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- CEO
- Mohammad Jonaid Shafiq
- Full Time Employees
- 4,031
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Dhaka Bangladesh
- IPO Date
- Oct 18, 2022
- Website
- navanapharma.com
- Similar Companies
- Business
- Navana Pharmaceuticals PLC is a Bangladesh-based pharmaceutical company engaged in the development, manufacturing, marketing, and distribution of generic pharmaceutical formulations for human healthcare and veterinary applications. The company operates through two primary business divisions: the Human Health Division and the Veterinary Division. Its human healthcare portfolio spans multiple therapeutic categories, including anti-infectives and systemic antibiotics (Faropen, Fixcef, Navacef, Flubiotic, and Itracon); antidiabetic agents (Aloglip, Glix, Diplin, and NV-Met); cardiovascular medications (Tabis, L-Amlo, Olmepin, Nestor, and Clonipres); gastrointestinal remedies (Dextac EC); respiratory medicines (Arokast and Brox); central nervous system and neurological drugs (Nortin, Pregan, and Myobac); analgesics and anti-inflammatory therapies (Loxodol); dermatological preparations (Sulderm); and ophthalmic formulations (Iclear and Alleloc). The Veterinary Division develops animal health solutions for poultry, livestock, and aquaculture segments, featuring veterinary antimicrobials (C-Flo Vet, D-Vet, Enro-10, Navamox Vet, Resmulin, Tilcon Vet, and Tylos Vet); antiparasitics and anticoccidials (Coczul Vet and Navacox); and animal feed supplements, tonics, and vitamins (Nephrosan, Nava Choline 75, Navaton Vet, and Vital B). Navana Pharmaceuticals produces dosage forms including solid oral tablets, capsules, dry powder suspensions, syrups, small volume parenterals, dry powder injectable vials, ophthalmic drops, creams, and ointments at its WHO cGMP-compliant manufacturing complex in Rupshi, Narayanganj, which houses dedicated general, penicillin, cephalosporin, and sterile parenteral units. In recent strategic developments, the company has undertaken an investment of approximately 145.27 crore Bangladeshi Taka to construct a new five-storey generic production unit designed to increase annual output capacity by approximately one billion units; reallocated its initial public offering proceeds to fast-track facility modernization and expansion with project completion timelines extending through late 2025; and initiated strategic diversification into the herbal medicine manufacturing segment. The company serves the domestic healthcare system through nationwide distribution and exports products to approximately fifteen countries across Asia and Africa. Founded in 1986 as part of Jahurul Islam Company, converted to a public limited company in 2020, and listed on the Dhaka Stock Exchange and Chittagong Stock Exchange, Navana Pharmaceuticals PLC is headquartered in Dhaka, Bangladesh.